Tyra Biosciences, Inc. Income Statement
TYRA / Health Care|5 years of annual SEC 10-K data (FY2020-FY2024)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 5 fiscal years. All figures from audited SEC 10-K filings.
Key Data Points
- Altman Z-Score 6.83 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| SG&A Expense | $24.1M | $17.4M | $15.9M | $5.7M | $2.1M |
| R&D Expense | $80.1M | $62.5M | $43.0M | $20.6M | $7.2M |
| Operating Income | -$104.2M | -$79.9M | -$58.9M | -$26.3M | -$9.3M |
| Income Tax | $0 | $0 | $2.0K | $1.0K | $1.0K |
| Net Income | -$86.5M | -$69.1M | -$55.3M | -$26.3M | -$9.3M |
| EPS (Basic) | -$1.51 | -$1.62 | -$1.32 | -$1.91 | - |
| EPS (Diluted) | -$1.51 | -$1.62 | -$1.32 | -$1.91 | - |
| Shares Outstanding | 57.2M | 42.7M | 41.9M | 13.8M | 1.5M |